Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis

Abstract

(Stem Cell Reports 3, 115–130; July 8, 2014) In the originally published version of our paper, the wrong data was used to generate Figure 4A: the hES-MSC line used to generate the figure was not the hES-MSC(MA09) line stated in the figure legend; instead, an hES-MSC line generated via another method, which was not described in the paper, was used. This mistake was uncovered during a recent internal data review. A correct version of Figure 4 now appears below. The altered figure does not affect the results and conclusion of the paper. We apologize for the oversight and for any confusion it has caused. Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple SclerosisWang et al.Stem Cell ReportsJune 5, 2014In BriefMesenchymal stem cells (MSCs) offer a potential therapy for multiple sclerosis. Xu, Lanza, and colleagues show that MSCs derived from human embryonic stem cells (hES-MSCs) significantly reduce clinical symptoms and prevent neuronal demyelination in a mouse EAE model of multiple sclerosis, and that the disease-inhibitory effect of hES-MSCs is remarkably greater than that of human bone-marrow-derived MSCs. Full-Text PDF Open Access